Shots:

• Sanofi to acquire all outstanding shares of Kiadis for $6.34/ share- representing an equity value of $358.76M. The offer price represents a premium of 272% over the closing price on Oct 30- 2020- a premium of ~247% over the 30 trading days VWAP and a premium of ~200% over the 90 trading days VWAP
• The transaction is expected to be completed in H1’21. The addition of Kiadis’ NK cell platform and pipeline of cell-based cancer immune-therapeutics & infectious disease therapies complements Sanofi’s existing therapeutic expertise
• In July’2020- Sanofi licensed Kiadis’ pre-clinical K-NK004 program for MM. Sanofi’s infrastructure and capabilities will be leveraged to advance the development of Kiadis’ pipeline

  Ref: Sanofi | Image: Kiadis